Charles Schwab Investment Management Inc. increased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 1.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 328,034 shares of the company's stock after acquiring an additional 5,438 shares during the period. Charles Schwab Investment Management Inc. owned about 0.68% of Axsome Therapeutics worth $27,755,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. R Squared Ltd bought a new stake in Axsome Therapeutics in the 4th quarter worth $64,000. KBC Group NV lifted its position in shares of Axsome Therapeutics by 40.5% in the 4th quarter. KBC Group NV now owns 1,336 shares of the company's stock worth $113,000 after purchasing an additional 385 shares during the period. Moors & Cabot Inc. purchased a new position in shares of Axsome Therapeutics during the third quarter valued at about $200,000. Whalen Wealth Management Inc. purchased a new position in shares of Axsome Therapeutics during the third quarter valued at about $236,000. Finally, Flower City Capital bought a new position in shares of Axsome Therapeutics in the 4th quarter worth approximately $254,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on AXSM. Royal Bank of Canada boosted their price target on Axsome Therapeutics from $143.00 to $192.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 19th. Robert W. Baird increased their price target on shares of Axsome Therapeutics from $132.00 to $160.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Leerink Partners boosted their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an "outperform" rating in a report on Monday, February 10th. Cantor Fitzgerald reiterated an "overweight" rating and set a $153.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Finally, HC Wainwright restated a "buy" rating and issued a $200.00 price target on shares of Axsome Therapeutics in a research note on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $167.36.
View Our Latest Report on Axsome Therapeutics
Axsome Therapeutics Price Performance
NASDAQ:AXSM traded up $0.52 on Friday, reaching $126.79. 420,928 shares of the company's stock traded hands, compared to its average volume of 641,314. The firm has a market cap of $6.18 billion, a PE ratio of -21.17 and a beta of 0.99. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. The stock has a 50-day simple moving average of $115.62 and a 200-day simple moving average of $99.84. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.01. The company had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. Equities research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.
Insider Activity at Axsome Therapeutics
In other news, CFO Nick Pizzie sold 3,000 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at $5,529,450.09. This represents a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 22.40% of the stock is owned by corporate insiders.
About Axsome Therapeutics
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Featured Stories
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
